ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Utility of dd-cfDNA in TCMR 1A and Borderline Allograft Rejection

E. Stites1, D. Kumar2, O. Olaitan3, G. Gupta2

1University of Colorado, Aurora, CA, 2Virginia Commonwealth University, Richmond, VA, 3Rush University, Chicago, CA

Meeting: 2020 American Transplant Congress

Abstract number: D-262

Keywords: Biopsy, Kidney transplantation, Rejection, T cells

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: Biomarkers, Immune Assessment and Clinical Outcomes

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Reassessing Tubulitis and Interstitial Infiltrate: Creating a New Probabilistic Definition of TCMR
  • Donor Derived Cell Free DNA (dd-cfDNA) and Gene Expression Signatures of Antibody-Mediated Rejection (ABMR) May Improve Accuracy of ABMR Diagnosis (Dx)

*Purpose: The value of donor-derived cell-free DNA (dd-cfDNA, AlloSure) as a molecular marker for the early diagnosis of mild T-cell mediated rejection (Banff TCMR 1A and borderline lesions) remains unclear based upon previous studies. This could be partly related to the fact that early histologic lesions used to characterize TCMR lesions can be non-specific. In addition, there may be significant inter-observer variability between biopsy interpretation that may result in over or under-diagnosis of histologic lesions.

*Methods: From June 2017 to May 2019, 79 patients across 11 transplant centers with biopsy defined TCMR 1A (n = 52) or Borderline Rejection (n = 27) (Banff 2017 criteria) were assessed. Patients were stratified by a median AlloSure dd-cfDNA >0.5% (n = 42) and ≤0.5% (n = 37) as well as by protocol biopsy and ‘for cause’ biopsy.

*Results: Using a dd-cfDNA cut off of 0.5%, there were no differences in patient demographics, the proportion of patients who had ‘for cause’ or protocol biopsies, or the proportion of patients across centers. Patients with elevated levels of dd-cfDNA (>0.5%) were associated with adverse outcomes including a mean decline in estimated glomerular filtration rate of 8.5% over a follow-up period of 6 months, compared to no decline in patients <0.5% (p=0.0040). 17/42 (40.5%) patients with dd-cfDNA >0.5% developed de novo donor-specific antibodies compared to 1/37 patients (2.7%) with dd-cfDNA <0.5% (p<0.0001). 9/42 (21.4%) of patients with dd-cfDNA >0.5% also had future or persistent rejection compared to none of the patients with dd-cfDNA <0.5% (p=0.0028).

*Conclusions: Not all TCMR1A/borderline is associated with adverse outcomes, and therefore likely represents a composite of more versus less aggressive pathologic states. There is an unmet need for additional diagnostic tools to strengthen the interpretation of the Banff system. Based upon these results, dd-cfDNA may provide a more complete characterization of rejection heterogeneity and valuable clinical information for high vs low risk lesions, allowing better understanding of allograft prognosis.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Stites E, Kumar D, Olaitan O, Gupta G. Utility of dd-cfDNA in TCMR 1A and Borderline Allograft Rejection [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/utility-of-dd-cfdna-in-tcmr-1a-and-borderline-allograft-rejection/. Accessed February 27, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Penis Transplantation: First U.S. Experience.
      • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
      • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
      • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
      • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.